

October 1, 2007

Press Release

Mitsubishi Tanabe Pharma Corporation

Establishment of Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation (Osaka, Japan; President, Representative Director & CEO, Natsuki Hayama) announced today that the company was created through the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma Corporation.

Mitsubishi Tanabe Pharma Corporation will work on R&D for the creation of new drugs which are globally competitive as well as using business platform strengthened by this merger to accelerate the development of business operations overseas and establish at an early stage a position as an international drug discovery corporation aiming at the future. In addition, the company will also be positive in taking up the challenges presented by new business opportunities in response to changes in medical environment, such as generic business and personalized medicine. Along with contributing to the health of people around the world, Mitsubishi Tanabe Pharma Corporation will continuously develop activities in order to maximize corporate value.

1. Profile of Mitsubishi Tanabe Pharma Corporation

Business Name	Mitsubishi Tanabe Pharma Corporation
Head Office	3-2-10 Doshomachi, Chuo-ku, Osaka
Capital	¥50 billion
Representatives	Natsuki Hayama President and Representative Director Chief Executive Officer Takeshi Komine Representative Director Executive Vice President
Description of Business	Manufacture, marketing, export and import of ethical drugs, OTC drugs, diagnostic agents and chemical products, bulk powders, etc.

2. Website Address

<http://www.mt-pharma.co.jp>

3. Fiscal 2010 Business Objectives

Sales	¥480 billion
Synergistic effects	¥27 billion
Operating income (prior to amortization of goodwill)	¥110 billion
Amortization of goodwill	¥10 billion
Operating income	¥100 billion

4. Basic Strategy

(1) Prompt Establishment of a Position as a Global Research-driven Pharmaceutical Company

- Use the drug discovery capabilities and business platform strengthened by this merger to accelerate the development of overseas business.
- Set “diabetes and hyper lipidemia,” “cerebral nerve diseases” and “renal and urological diseases” as focus disease areas, fuse and promote the further strengthening of the theme discovery and optimization capabilities that were the strengths of both former companies, and aim at the continuous creation of new drugs that are globally competitive.
- Implement global development at an early stage, including the active promotion of phase III clinical trials in Europe and the U.S.A. for Cholebine, a treatment drug for hyperphosphatemia, and MP-146, a drug for chronic kidney failure.

(2) Enhancement of Domestic Market Presence

- Enhance the domestic market presence using the top-tier marketing capabilities achieved through the merger.
- Further strengthen the strategic areas of immunology (Remicade) and cerebrovascular diseases (Radicut, etc.) that the companies have cultivated to this point and continue the high quality information provision activities that are the most trusted in these areas, in which products have been differentiated, to establish a position as the leading company in the immunology and cerebral disease areas.
- Concentrate management resources on the four key products of Anplag, an anti-platelet agent, Talion, an anti-allergy agent, Urso, an agent for improving hepatic, biliary and digestive functions, and Tanatril, an anti-hypertension, and aim at the maximization of synergistic effects.

(3) Aim at Becoming a Distinctive Pharmaceutical Company

- Respond to changes in medical environment and be positive in taking up the challenges presented by new business opportunities, such as participation in generic drug business and efforts towards personalized medicine.
- In the generic drug business that the company will newly enter, utilize to the full all of the company's reliability assurance, R&D, manufacturing and distribution foundations to realize a complete, high quality product line-up and stable supply, and provide reliable generic products that both patients and healthcare professionals can use with peace of mind.
- Through tie-ups with all of the companies of the Mitsubishi Chemical Holdings Corporation Group, make positive efforts not only towards conventional treatment responsive to mass medicine, but also towards so-called personalized medicine - targeted medicine that focuses on the individual pathologies of patients.

Contact for further information on this press release:

Corporate Communications Department

Mitsubishi Tanabe Pharma Corporation

Tel: +81-6-6205-5211